[Skip to Content]
Sign In
Individual Sign In
Create an Account
Institutional Sign In
OpenAthens Shibboleth
Purchase Options:
[Skip to Content Landing]
Correction
March 21, 2007

Omission of Text in Financial Disclosures in: Tolterodine and Tamsulosin for Treatment of Men With Lower Urinary Tract Symptoms and Overactive Bladder: A Randomized Controlled Trial

JAMA. 2007;297(11):1195. doi:10.1001/jama.297.11.1195

Omission of Text in Financial Disclosures: In the Original Contribution entitled “Tolterodine and Tamsulosin for Treatment of Men With Lower Urinary Tract Symptoms and Overactive Bladder: A Randomized Controlled Trial” published in the November 15, 2006, issue of JAMA (2006;296:2319-2328), text in 2 sentences of the financial disclosure was inadvertently omitted. The sentence that read “Dr Roehrborn is also a consultant for GlaxoSmithKline, Sanofi Aventis, and Lilly ICOS, a consultant for Allergan and Esprit, a speaker for Astellas and Esprit, and a study investigator for Allergan and Q-Med” should have read “Dr Roehrborn is also a consultant for GlaxoSmithKline, Sanofi Aventis, and Lilly ICOS, and is a study investigator for Lilly ICOS. Dr Rovner is a paid consultant, speaker, meeting participant, and study investigator for Pfizer; a consultant for Allergan and Esprit; a speaker for Astellas and Esprit; and a study investigator for Allergan and Q-Med.”

×